Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Assembly Biosciences (ASMB) over the last 11 years, with Q3 2025 value amounting to -$158.3 million.

  • Assembly Biosciences' Cash from Investing Activities fell 74632.06% to -$158.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$141.4 million, marking a year-over-year decrease of 23044.38%. This contributed to the annual value of $40.2 million for FY2024, which is 15810.26% up from last year.
  • As of Q3 2025, Assembly Biosciences' Cash from Investing Activities stood at -$158.3 million, which was down 74632.06% from $17.0 million recorded in Q2 2025.
  • In the past 5 years, Assembly Biosciences' Cash from Investing Activities ranged from a high of $33.0 million in Q1 2022 and a low of -$158.3 million during Q3 2025
  • For the 5-year period, Assembly Biosciences' Cash from Investing Activities averaged around -$2.4 million, with its median value being $10.0 million (2023).
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first surged by 41088.44% in 2022, then crashed by 74632.06% in 2025.
  • Assembly Biosciences' Cash from Investing Activities (Quarter) stood at -$8.5 million in 2021, then soared by 295.21% to $16.6 million in 2022, then plummeted by 641.32% to -$89.7 million in 2023, then soared by 92.53% to -$6.7 million in 2024, then tumbled by 2263.66% to -$158.3 million in 2025.
  • Its Cash from Investing Activities was -$158.3 million in Q3 2025, compared to $17.0 million in Q2 2025 and $6.6 million in Q1 2025.